Georgetown, Texas-based drug developer DisperSol Technologies, LLC, has raised more than $10 million in a round of financing to expand their product pipeline and assure the development of their drug portfolio. The new financing, which included Research Corporation Technologies along with some of the company’s original investors, will enable DisperSol to strengthen their industry partnerships, as well as improve the bioavailability profiles of their drugs within the regulatory processes, as announced by the company in a press release.
DisperSol Technologies his dedicated to the development and manufacturing of pharmaceutical products based on the company’s processing technology KinetiSol, which enables the design of insoluble drug products with application in health areas with unmet medical needs. The technology works by allowing the solubility enhancement of heat-sensitive and organic solvent-insoluble drugs that are promising therapeutic options.
“We are very impressed with DisperSol’s capabilities and game changing platform,” said the president for Biotechnologies at the Research Corporation Technologies, Shaun Kirkpatrick. “KinetiSol’s success in enhancing the bioavailability of temperature-sensitive and organic solvent insoluble drugs uniquely fills a growing market need. Importantly, the technology has been proven at commercial scale, and we have not seen any other manufacturing method in the field with KinetiSol’s cost advantages coupled to the competitive advantages of new intellectual property for each new formulation.”
“We are looking forward to partnering with DisperSol’s management team as they develop new products and expand the adoption of this unique technology throughout the pharmaceutical industry,” Kirkpatrick added about the system that has already been part of several programs in collaboration with other pharmaceuticals. KinetiSol has also been proven efficient, as it enables a larger availability to have the projects ready for manufacturing in shorter periods of time.
DisperSol is one of the biotech companies that set up shop in the second building of the Texas Life-sciences Collaboration Center (TLCC), whose main purpose is to increase the biotech sector and local manufacturing of innovative, life-saving medical technologies in Texas. The life sciences-focused accelerator, which is located at 111 Cooperative Way in southern Georgetown, started the construction of its second building, a sprawling, 15,000 square-foot structure in June, 2013 in order to improve Georgetown’s commercial viability with a workforce that generates high wages for taxes and local spending.